SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

X-82

Item No. 38765

CAS Registry No.:	1013920-15-4
Formal Name:	N-[(3S)-1-[(dimethylamino)carbonyl]-3-pyrrolidinyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Synonyms:	CM082, Vorolanib
MF:	$C_{23}H_{26}FN_5O_3$
FW:	439.5
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

X-82 is supplied as a solid. A stock solution may be made by dissolving the X-82 in the solvent of choice, which should be purged with an inert gas. X-82 is soluble in acetonitrile.

Description

X-82 is a multi-kinase inhibitor.[1] It inhibits VEGFR2, PDGFRβ, FMS-related tyrosine kinase 3 (FLT3), and c-Kit (IC_{50}s = 1.12, 0.13, 0.63, and 0.14 nM, respectively) and is selective for these kinases over RET and AMP-activated kinase α1 (AMPKα1; IC_{50}s = 74.1 and 352.2 nM, respectively). X-82 inhibits VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC_{50} = 31 nM).[2] It decreases VEGF-induced capillary tube formation in HUVECs when used at a concentration of 1 µM and reduces FBS-induced migration of HUVECs at 0.01 or 0.1 µM. *In vivo*, X-82 (80 mg/kg per day), alone and in combination with the EGFR inhibitor gefitinib (Item No. 13166), reduces tumor volume and growth in an HCC827 non-small cell lung cancer (NSCLC) mouse xenograft model.

References

1. Liang, C., Yuan, X., Shen, Z., *et al.* Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity. *Mol. Ther. Oncolytics* **24,** 577-584 (2022).
2. Zhang, K., Wang, L., Wei, A., *et al.* CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer *in vitro* and *in vivo*. *Thorac. Cancer* **11(6),** 1566-1577 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM